January 18, 2023
As Cell Therapy Gains Ground, Efforts Emerge to Improve CAR T-Manufacturing
Related News
-
April 22, 2024Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
-
April 18, 2024
Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies, to Resolve Manual QC Processing Bottleneck and Extend IDMO Capabilities from Manufacturing Through Quality Control
-
March 26, 2024
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
